Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.
Breakthrough for prostate cancer patients as NHS now offers life-extending drug - The new medication is suitable for patients ...
Prostate cancer is the second-most common cancer in men. A new study from Thomas Jefferson University uncovered a new ...
New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.
ZERO Prostate Cancer (ZERO), announces the 2026 Veterans' Action Convening, a national gathering committed to strengthening ...
University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...
An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.
News-Medical.Net on MSN
PSA-based tool improves decision making for prostate cancer screening and treatment
Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...
The PROSTaid group, which meets monthly at The Cradock Arms in Leicester, aims to create a support group for men so they can ...
To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...
This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results